Related Experiment Video
Updated: Jul 14, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in
Rita Alloway1, Steven Steinberg, Kassem Khalil
1Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH, and California Institute of Renal Research, Sharp Memorial Hospital, San Diego, CA, USA.
Abstract:
Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury III: Clinical Manifestations
Continuous Renal Replacement Therapy
